1. Case description {#s0005}
===================

Fusariosis in patients with prolonged neutropenia have a dismal prognosis and survival is extremely low at 4% [@bib2]. *Fusarium* species are plant pathogens found in air and soil, and enter the human body through inhalation, ingestion, and heel or toe fissures. Early detection of *Fusarium* infections is difficult due to lack of specific laboratory assays. Management is challenging due to variability of anti-fungal susceptibilities and lack of optimal treatment strategy [@bib1]. We report the successful treatment of a patient with relapsed AML and invasive sino-pulmonary and cutaneous *Fusarium solani* infection during a course of salvage chemotherapy and subsequent allogeneic SCT.

A 66-year-old Caucasian male with diabetes, hyperlipidemia and obstructive sleep apnea presented to the NIH Clinical Center with relapsed AML. At the time of presentation, he was noted to have firm, non-tender, erythematous subcutaneous nodules on his bilateral anterior lower limbs and painful edematous feet ([Fig. 1](#f0005){ref-type="fig"}A/B). A skin biopsy of one of these nodules was interpreted as septal panniculitis.Fig. 1A- Left foot, ankle and lower legs showing erythema, swelling and nodules. B- Enlarged view of left medial heel nodule. C- Baseline CT chest. D- Week 3 CT chest with nodules and infiltrates (arrows). E- Week 15 CT chest with resolution of nodules and infiltrates. F- GMS 20×, showing *Fusarium* hyphae and spores identified in the left middle turbinate. G- H&E 20×, showing hyphae and spores in the bone of the nasal turbinate and surrounding soft tissues.Fig. 1

The patient was consented to treatment on clinical trial NCT02527447 and received treatment with salvage chemotherapy of mitoxantrone 12 mg/m^2^/day IV on days 1--3, etoposide 200 mg/m^2^/day continuous IV infusion (CIV) on days 8--10, and cytarabine 500 mg/m^2^/day CIV on days 1--3 and 8--10 (EMA). Infectious prophylaxis with caspofungin was given during chemotherapy and oral posaconazole was started after chemotherapy as per institutional standard. During the third week after chemotherapy, new painful nodules appeared on his trunk, neck, upper arm and the plantar aspect of his foot. In addition, there was interval development of bilateral focal patchy nodular pulmonary infiltrates with ground glass and reticular appearance on chest CT imaging ([Fig. 1](#f0005){ref-type="fig"}C/D), followed by development of paranasal sinusitis. The patient underwent bronchoscopy with broncho-alveolar lavage, skin biopsy of a palpable nodule, and sinus biopsy. *Fusarium solani* was isolated from all three of these sites ([Fig. 1](#f0005){ref-type="fig"}F/G).

Fungal susceptibilities showed amphotericin minimum inhibitory concentration (MIC): 2 mcg/mL and terbinafine MIC: 2 mcg/mL and resistance to micafungin, posaconazole and voriconazole. The patient was initially treated with amphotericin, however, subsequent CT chest one week later showed progression of pulmonary infiltrates, and terbinafine and voriconazole were added despite fungal susceptibilities. Bone marrow examination on day 35 showed a hypocellular (5%) marrow with trilineage hypoplasia and no definitive evidence of AML. Peripheral blood neutrophils were absent. A course of filgrastim daily injections was administered for ten days, at which time his absolute neutrophil count (ANC) recovered to greater than 2.0 × 10^9^/L. The total duration of severe neutropenia with ANC less than 0.1 × 10^9^/L was 40 days. At the time of ANC recovery, the result of his Fungitell serum assay (Beacon diagnostics) was positive (167 pg/mL, positive = \> 80 pg/mL), however, the appearance of his skin nodules improved, and pulmonary and sinus radiographic abnormalities stabilized during this time.

Complete remission with no evidence of minimal residual disease was confirmed on bone marrow examination on day 73. At day 100 following salvage chemotherapy, the CT showed resolution of the nodules ([Fig. 1](#f0005){ref-type="fig"}E) and Fungitell result normalized (\< 60 pg/mL, [Fig. 2](#f0010){ref-type="fig"}A). He received consolidation chemotherapy with clofarabine 20 mg/m^2^ IV on days 1--5, followed by haplo-identical SCT 10 days later. A two-step approach [@bib3] was used as a myeloablative conditioning regimen including fludarabine 120 mg/m^2^, total body irradiation (12 Gy), and a donor lymphocyte infusion (2 × 10^8^/kg CD3^+^T cells) which was followed by cyclophosphamide 120 mg/kg prior to CD34^+^ selected peripheral blood stem cell infusion. GVHD prophylaxis was with sirolimus (trough goal 5--12 ng/mL) along with ultra-low dose interleukin-2 (ULD-IL2) 100,000 international units/m2(clinical trial NCT02226861). Micafungin was used as anti-fungal prophylaxis until day 33 following post-transplant. No other anti-fungal prophylaxis therapy was used.Fig. 2A- Relationship between ANC recovery, antifungal therapy and reduction in (1→3)-β-D-glucan(B-D-Glucan) levels. Clo = Clofarabine. B- Use of granulocyte infusions to minimize neutropenia during allogeneic transplantation (SCT). Timing of granulocyte infusions shown with arrow. Note: Transplant day -11 is chemotherapy day 106. SCT conditioning done with Fludarabine (Flu), Cyclophosphamide (Cy) and Total Body Irradiation (TBI).Fig. 2

The patient became neutropenic (ANC \< 0.5 × 10^9^/L) from clofarabine consolidation 10 days prior to stem cell graft infusion, and the time to engraftment (ANC \> 0.5 × 10^9^/L) was 12 days following transplant, for a total of 22 days of peri-transplant neutropenia. Due to the anticipated neutropenia, granulocyte infusions from G-CSF stimulated donors were scheduled for 5 doses during his transplant course ([Fig. 2](#f0010){ref-type="fig"}B) with average dose more than 0.6 × 10^9^/kg. Granulocyte donors were selected based on negative CMV serology and to avoid any HLA class I and II antigen mismatch with the patient or haplo-identical SCT donor. Granulocyte infusions were well tolerated without complications. G-CSF was not used in the peri-transplant period. The patient is now 14 months' post haplo-identical SCT and remains in complete remission with no evidence of infection.

The incidence of fusariosis in allogeneic-SCT ranges from 0.2% to 0.6% and in acute leukemia from 0.1% to 0.3% [@bib1]. There is an increased incidence of *Fusarium* infection in immunosuppressed patients and in AML patients compared to other hematological malignancies [@bib2], [@bib4]. In an immunocompromised host, lack of a normal immune response allows for angio-invasion of *Fusarium,* causing necrosis and disseminated infections.

Skin involvement is present in 68--70% of cases of fusariosis [@bib5]. As skin is one of the primary sources of entry, thorough skin examination and biopsy of suspicious nodules should be considered. Sinus involvement occurs in 80% of cases of disseminated fusariosis, with manifestations including facial or periorbital cellulitis and sinus congestion [@bib6]. Pulmonary nodules have been reported in 80% of patients with respiratory symptoms, with a range in diameter from 0.3cm to 2.7 cm [@bib7]. Nodules greater than 1 cm should raise the suspicion for invasive fungal infection [@bib8].

The role of galactomannan and (1→3)-β-D-glucan testing in fusariosis is unknown. A positive (1→3)-β-D-glucan test combined with a negative galactomannan is thought to favor diagnosis of other hyalohyphomycosis but aspergillosis [@bib1]. Exposure to antibiotics or antifungals can cause variable sensitivity to galactomannan and/or (1→3)-β-D-glucan tests [@bib9]. Antifungal susceptibility testing is recommended, however, there is lack of clear evidence to support the relation between fungal susceptibilities and clinical efficacy [@bib1].

Host factors that predict poor outcomes of *Fusarium* infection in patients with hematological malignancies are prolonged profound neutropenia (\> 14 days and \< 100/mm^3^, respectively) and therapy with corticosteroids [@bib6]. Colony stimulating factors have a role in the treatment of life-threatening infections due to chemotherapy-associated neutropenia, and in shortening the duration of prolonged neutropenia to reduce the incidence of febrile neutropenia [@bib10]. However, these agents should be used with caution in patients with active AML to avoid stimulation of leukemic blast proliferation [@bib11].

Our case report provides further evidence that pre-existing fungal infections should not preclude SCT for hematologic malignancies [@bib12]. For this patient, the short time to engraftment, in combination with granulocyte infusions minimized the duration of post-transplant neutropenia, which helped control the *Fusarium* infection. A multi-disciplinary approach with involvement of the Hematology, Infectious Disease and Transfusion Medicine services to maintain adequate neutrophil counts prior to engraftment was successful in this case. Granulocyte infusions have become less complicated and more effective using HLA- matched donors [@bib13]. Mobilization regimens including G-CSF and dexamethasone have increased granulocyte yield to more than 0.6 × 10^9^/kg [@bib12].

Disseminated *Fusarium solani* in immunocompromised patients has a high mortality rate, is typically refractory to anti-fungal treatment, and adequate neutrophil counts appear to be an important determinant of survival [@bib1]. Successful outcomes, as in the case, are underreported in the literature. This case illustrates the early detection, successful interventions and outcome for a systemic invasive fungal infection that is typically fatal. We used thorough skin examinations, early diagnostic interventions, (1→3)-β-D-glucan serum monitoring during treatment, serial CT scans, G-CSF to expedite neutrophil recovery and granulocyte infusions to minimize duration of peri-transplant neutropenia. Adequate neutrophil counts were critical to the management of this invasive fungal infection and allowed for successful definitive treatment of relapsed AML.
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